<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186966</url>
  </required_header>
  <id_info>
    <org_study_id>TRIAL</org_study_id>
    <secondary_id>TRIAL Relapsed AML 2001/01</secondary_id>
    <nct_id>NCT00186966</nct_id>
  </id_info>
  <brief_title>Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Childhood Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International BFM Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Childhood Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multicenter open label randomized phase III trial in children with&#xD;
      relapsed and refractory acute myeloid leukemia (AML) such a disease. The main purpose of this&#xD;
      study is to determine the efficacy and toxicity of liposomal daunorubicin when added to&#xD;
      fludarabine, ara-C and G-CSF(FLAG) in children with relapsed and refractory AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives of this trial are:&#xD;
&#xD;
        -  To determine the toxicity of liposomal daunorubicin when added to FLAG, in terms of&#xD;
           mucosal toxicity, bone marrow aplasia, short- and long-term cardiotoxicity and other&#xD;
           side effects as compared to patients treated with FLAG only.&#xD;
&#xD;
        -  To determine the long-term clinical outcome prospectively in a large group of children&#xD;
           with refractory and relapsed acute myeloid leukemia.&#xD;
&#xD;
        -  To determine the changes in minimal residual disease over time, and the prognostic&#xD;
           significance of minimal residual disease determined at various time-points.&#xD;
&#xD;
        -  To determine the relation between in vitro cellular drug resistance and clinical and&#xD;
           cell biological features, minimal residual disease and clinical outcome in this patient&#xD;
           group&#xD;
&#xD;
        -  To determine the pharmacokinetics of liposomal daunorubicin in relation to its toxicity&#xD;
           and efficacy&#xD;
&#xD;
      Reinduction treatment will be done with 2 courses of combination chemotherapy, with FLAG&#xD;
      (fludarabine, ara-C and G-CSF) in both courses as standard treatment. In the first course&#xD;
      there will be a randomisation for liposomal daunorubicin (DaunoXomeÂ®) to be added or not. The&#xD;
      second course should always concern FLAG. If patients have &gt; 20% of blasts in the bone marrow&#xD;
      after the 1st course, or if they are not in complete remission (CR) after the 2nd course,&#xD;
      they will go off protocol. Patients in CR after reinduction treatment can immediately proceed&#xD;
      to stem cell transplantation. Consolidation chemotherapy should be given if SCT is delayed. A&#xD;
      3rd course of intensive chemotherapy (VP16 and continuous infusion with cytarabine) is the&#xD;
      general recommendation. In selected patients, a low intensity consolidation may be preferred,&#xD;
      and such a schedule is described as well. The type of SCT is based on the risk-group.&#xD;
      Preferably, a matched sibling donor (MSD) SCT is performed. If a MSD is not available all&#xD;
      patients are candidates for a matched unrelated donor (MUD) SCT. If a MUD is also not&#xD;
      available, patients with primary refractory disease, early relapse (within 1 year from&#xD;
      diagnosis), or greater than or equal to 2nd relapse, are candidates for the more experimental&#xD;
      haplo-identical donor (HID) SCT in view of the dismal prognosis. However, patients with a&#xD;
      late relapse (&gt;1 year from initial diagnosis) have a better prognosis and should be offered&#xD;
      an autologous SCT if a MSD or MUD SCT is not possible. Only in case of autologous SCT,&#xD;
      maintenance treatment and/or adjuvant immunotherapy could be considered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>8-9 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity between two arms</measure>
    <time_frame>8-9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>FLAG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FLAG and LP Dox</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>FLAG</arm_group_label>
    <arm_group_label>FLAG and LP Dox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>FLAG</arm_group_label>
    <arm_group_label>FLAG and LP Dox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic stem cell transplant</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>FLAG</arm_group_label>
    <arm_group_label>FLAG and LP Dox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>FLAG</arm_group_label>
    <arm_group_label>FLAG and LP Dox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children and adolescents less than eighteen years of age at start of chemotherapy.&#xD;
&#xD;
          -  Subject has one of the following: Primary refractory AML, first relapsed AML, second&#xD;
             or subsequent relapsed AML and was not previously treated according to this particular&#xD;
             protocol&#xD;
&#xD;
          -  Subjects with a combined relapse, or an isolated extramedullary relapse, or a bone&#xD;
             marrow relapse are eligible, also for randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic cardiac dysfunction.&#xD;
&#xD;
          -  Inadequate performance score.&#xD;
&#xD;
          -  Any other organ dysfunction that will interfere with the administration of the&#xD;
             therapy.&#xD;
&#xD;
          -  FAB type M3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Rubnitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <results_reference>
    <citation>Kaspers J, Zimmermann M, Fleischhack G, Tamminga R, Gibson B, Armendariz H, Dworzak M, Ha S, Hovi L, Maschan A, Philippe N, Razzouk B, Rizzari C, Smisek P, Smith O, Stark B, Will A, Creutzig U. Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01. 2006 ASH Annual Meeting Abstracts 108: 2013.</citation>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. G.J.L. Kaspers, MD PhD / Principal Investigator</name_title>
    <organization>Dutch Childhood Oncology Group, the Hague, the Netherlands</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

